Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)

NCT01653678
Conditions
Hypertension
Interventions
Vitamin D-3 (cholecalciferol), 2000 IU, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 99 Years
Enrollment
25,875 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA + DHA in a SMEDS Formulation

NCT03443076
Conditions
Bioavailability
Interventions
EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved)
Dietary Supplement · Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Boca Raton, Florida • Chicago, Illinois
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL

NCT01696435
Conditions
Depression, Depressive Symptoms, Mood
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Fish oil placebo, Vitamin D placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
18,353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Vitamin D Supplementation on Cardiac Structure and Function

NCT01630213
Conditions
Cardiovascular Disease
Interventions
Vitamin D3 + fish oil/fish oil placebo, Vitamin D3 placebo + fish oil/fish oil placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
1,025 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Aging
Interventions
Vitamin D3 (cholecalciferol), fish oil
Dietary Supplement · Drug
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Liver Disease, Short Bowel Syndrome
Interventions
Lovaza (omega-3-acid ethyl ester), Corn oil
Drug · Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cardiovascular Disease, HIV Infection
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Huntington Disease
Interventions
Ethyl-EPA (Miraxion™)
Drug
Lead sponsor
Amarin Neuroscience Ltd
Industry
Eligibility
35 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vascepa to Accelerate Lipoprotein Uptake and Elimination

NCT03885661
Conditions
Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions
Icosapent Ethyl 1000 MG [Vascepa]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Lovaza, placebo control
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pasadena, California
Not listed Phase 4 Interventional Accepts healthy volunteers

Lovaza Mechanisms of Action

NCT01301794
Conditions
Moderate Hypertriglyceridemia.
Interventions
Omega 3 fatty acid (Lovaza)
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Vitamin D and Omega-3 Trial (VITAL)

NCT01169259
Conditions
Cancer, Cardiovascular Disease
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed Not applicable Interventional Accepts healthy volunteers Results available

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

NCT01782352
Conditions
Age-related Macular Degeneration
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Essential Tremor
Interventions
Encora Therapeutics Tremor Reduction Device
Device
Lead sponsor
Encora, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Atrial Fibrillation
Interventions
Fish oil, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

NCT00771914
Conditions
Increased Drug Resistance
Interventions
Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Conditions
Bipolar Disorder
Interventions
Ethyl Eicosapentaenoic Acid
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional

Breast, Omega 3 Free Fatty Acid, Ph 0

NCT02996240
Conditions
Breastcancer
Interventions
Omega-3 FFA
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Terminated Phase 4 Interventional Results available

Effects of Fish Oil on Post Ablation Arrhythmias

NCT00791089
Conditions
Atrial Fibrillation
Interventions
LOVAZA Omega 3-acid ethyl esters, LOVAZA, placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Colorectal Cancer, Lynch Syndrome
Interventions
Omega-3 fatty acid ethyl esters (2 gram)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas